Caribou Biosciences, Inc. (CRBU)
CRBUNASDAQ-GSBiotechnology: Biological Products (No Diagnostic Substances)
$0.3747
-0.0055 (-1.45%) today
Regular session, Nov 13, 12:09 PM ET
- Market cap
- $40.48m
- P/E
- –
- EPS, last 4 quarters
- $-1.03
- Dividend yield
- –
- Day range
- $0.3600 to $0.3800
- 52-week range
- $0.3646 to $2.49
- Average volume
- –
- Previous close
- $0.3802
Analysts
6 coveringHold2 buy, 4 hold, 0 sell
Targets a year out average $2.33, +521.8% from here
Earnings
next estimate $-0.2200Next report
Dec 2025
+15.2%
Mar 2026
+21.2%
Jun 2026
+27.3%
Sep 2026
+7.4%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $3.94m | $2.40m | $1.50m | $1.61m |
| Gross profit | $3.94m | $2.40m | $1.50m | $1.61m |
| Operating income | -$28.45m | -$26.28m | -$25.34m | -$27.64m |
| Net income | -$26.49m | -$25.09m | -$24.28m | -$26.61m |
Last four quarters: revenue $9.44m, margin -1085.0%, free cash flow -$92.99m
News
8 latest- Caribou Biosciences (CRBU) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?Zacks · 1 day ago
- Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Beats Revenue EstimatesZacks · Nov 5, 2026
- Castle Biosciences, Inc. (CSTL) Reports Q3 Loss, Beats Revenue EstimatesZacks · Nov 5, 2026
- Petrobras to Report Q3 Earnings: What's in the Cards for the Stock?Zacks · Nov 5, 2026
- Agilent Technologies' Q4 Earnings on Deck: What's in Store for the Stock?Zacks · Nov 5, 2026
- Caribou Biosciences, Inc. (CRBU) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks · Nov 4, 2026
- Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue EstimatesZacks · Nov 2, 2026
- Weekly Buzz: RHHBY, NVS, PFE Win FDA Nod; CRBU Scales Back; PCVX, ABBV Report Positive Trial Data RTTNews · Oct 9, 2026
The company
On October 6, 2026, Caribou Biosciences announced that it will explore strategic alternatives to maximize stockholder value, including the planned discontinuation of clinical trials and further development activities for two allogeneic CAR-T cell therapy programs, vispacabtagene regedleucel (vispa-cel) and CB-011. Prior to this announcement, Caribou was a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- cariboubio.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.